| 2027-07-01in 310 d | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | 4568.TDaiichi Sankyo | Phase 1 | Solid Tumors | Active, not recruiting |
| 2027-07-01in 310 d | HALO Clarity™ Cranial Alternating Current Stimulation Therapy for Adults With Moderate-to-Severe Insomnia | NXLNexalin Technology | Not applicable | Moderate to Severe Insomnia | Not yet recruiting |
| 2027-07-01in 310 d | A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy Participants | ONCBeOne Medicines | Phase 1 | Healthy Volunteers | Recruiting |
| 2027-07-01in 310 d | VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | VKTXViking Therapeutics, Inc. | Phase 3 | Weight Loss | Active, not recruiting |
| 2027-07-01in 310 d | VK2735 for Weight Management Phase 3 | VKTXViking Therapeutics, Inc. | Phase 3 | Weight Loss | Active, not recruiting |
| 2027-07-01in 310 d | Prospective G7 Dual Mobility Total Hip PMCF | ZBHZimmer Biomet | — | Clinical Outcomes, Functional Outcomes, Radiological Outcomes, Survivorship, Safety | Active, not recruiting |
| 2027-07-02in 311 d | A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | NVONovo Nordisk A/S | Phase 3 | Heart Failure | Active, not recruiting |
| 2027-07-04in 313 d | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | PFESeagen, a wholly owned subsidiary of Pfizer | Phase 1 | Myelodysplastic Syndromes | Recruiting |
| 2027-07-05in 314 d | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | AMGNAmgen | Phase 3 | Lung Cancer | Active, not recruiting |
| 2027-07-05in 314 d | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | BMYBristol-Myers Squibb | — | Psoriasis | Recruiting |
| 2027-07-06in 315 d | A Study of Eptinezumab in Pediatric Participants With Episodic Migraine | HLUN-B.COH. Lundbeck A/S | Phase 3 | Migraine | Recruiting |
| 2027-07-07in 316 d | Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis | AZNAstraZeneca | Phase 2 | Liver Fibrosis, Hepatic Cirrhosis | Recruiting |
| 2027-07-09in 318 d | A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity | AZNAstraZeneca | Phase 1 | Healthy Participants | Recruiting |
| 2027-07-09in 318 d | A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function | PFEPfizer | Phase 1 | Healthy | Recruiting |
| 2027-07-09in 318 d | A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | SNYSanofi | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting |
| 2027-07-10in 319 d | CLAARITY is a Prospective, Observational, Single-arm, Multi-center, Post-market US Study Designed to Evaluate the Safety and Performance of the ECLIPTIS Left Atrial Appendage Exclusion System for Exclusion of the Left Atrial Appendage (LAA) During Concomitant Open-heart Cardiac Surgery. | EWEdwards Lifesciences | — | Atrial Appendage | Not yet recruiting |
| 2027-07-10in 319 d | Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) | NTRANatera, Inc. | — | Colorectal Cancer | Recruiting |
| 2027-07-12in 321 d | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | NVONovo Nordisk A/S | Phase 2 | Obesity | Recruiting |
| 2027-07-15in 324 d | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | AZNAstraZeneca | Phase 3 | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active, not recruiting |
| 2027-07-15in 324 d | Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | SNYSanofi | Phase 3 | Multiple Sclerosis | Recruiting |
| 2027-07-16in 325 d | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | AZNAstraZeneca | Phase 1/2 | Gastric Cancer | Recruiting |
| 2027-07-16in 325 d | A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia | BMYBristol-Myers Squibb | Phase 2 | Anemia | Recruiting |
| 2027-07-18in 327 d | Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. | AMGNAmgen | Phase 3 | Vasculitis | Active, not recruiting |
| 2027-07-18in 327 d | A First-In-Human Study of ARO-033 in Adult Participants | ARWRArrowhead Pharmaceuticals | Phase 1 | Healthy Participants | Recruiting |
| 2027-07-19in 328 d | A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy | AZNAstraZeneca | Phase 1 | Solid Tumors | Recruiting |
| 2027-07-20in 329 d | A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults | MRNAModernaTX, Inc. | Phase 1 | Respiratory Syncytial Virus | Recruiting |
| 2027-07-21in 330 d | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. | SNYSanofi | Phase 2 | Crohn's Disease | Recruiting |
| 2027-07-22in 331 d | A Study of Oral E1018 in Healthy Adult Participants | 4523.TEisai Inc. | Phase 1 | Malaria, Healthy Participants | Active, not recruiting |
| 2027-07-22in 331 d | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | PFEPfizer | Phase 3 | Breast Cancer | Recruiting |
| 2027-07-22in 331 d | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | VRTXVertex Pharmaceuticals Incorporated | Phase 2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Active, not recruiting |
| 2027-07-23in 332 d | The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease | SNYSanofi | Phase 3 | Sickle Cell Disease | Recruiting |
| 2027-07-27in 336 d | Study of INCB123667 in Subjects With Advanced Solid Tumors | INCYIncyte Corporation | Phase 1 | Solid Tumors | Active, not recruiting |
| 2027-07-28in 337 d | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | AZNAstraZeneca | Phase 3 | Breast Cancer | Recruiting |
| 2027-07-28in 337 d | A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] | PFEPfizer | Phase 3 | Myositis | Recruiting |
| 2027-07-29in 338 d | A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE | AZNAstraZeneca | — | Non-cystic Fibrosis Bronchiectasis | Recruiting |
| 2027-07-29in 338 d | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis | SNYSanofi | Phase 2 | Colitis Ulcerative | Recruiting |
| 2027-07-30in 339 d | Volrustomig Priming Regimens Exploratory Phase II Platform Study | AZNAstraZeneca | Phase 2 | Lung Cancer | Recruiting |
| 2027-07-30in 339 d | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | AZNAstraZeneca | Phase 3 | Hypercholesterolaemia | Not yet recruiting |
| 2027-07-30in 339 d | A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia | BMYBristol-Myers Squibb | — | Acute Myeloid Leukemia | Recruiting |
| 2027-07-30in 339 d | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | IDYAIDEAYA Biosciences | Phase 1 | Esophageal Cancer | Recruiting |
| 2027-07-30in 339 d | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | INCYIncyte Corporation | Phase 2 | Fibrodysplasia Ossificans Progressiva (FOP) | Recruiting |
| 2027-07-30in 339 d | BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer | ONCBeOne Medicines | Phase 1 | Breast Cancer | Recruiting |
| 2027-07-30in 339 d | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | ONCYOncolytics Biotech | Phase 1/2 | Pancreatic Cancer | Active, not recruiting |
| 2027-07-30in 339 d | A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 | PFEPfizer | Phase 3 | Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo | Active, not recruiting |
| 2027-07-30in 339 d | French Prospective Multicentric Study in Real World | PODDInsulet Corporation | — | Type 1 Diabetes | Active, not recruiting |
| 2027-07-30in 339 d | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | RIGLRigel Pharmaceuticals | Phase 4 | Lung Cancer | Recruiting |
| 2027-07-31in 340 d | Study of Secutrelvir in Participants With COVID-19 | 4507.TShionogi | Phase 3 | COVID-19 | Not yet recruiting |
| 2027-07-31in 340 d | Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China | 4568.TDaiichi Sankyo | — | Gastric Cancer | Recruiting |
| Jul 2027≤ 340 d | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | ABBVAbbVie | Phase 3 | Ulcerative Colitis | Active, not recruiting |
| Jul 2027≤ 340 d | A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study) | ABBVAbbVie | — | Acute Myeloid Leukemia | Active, not recruiting |
| Jul 2027≤ 340 d | Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | ABBVAbbVie | Phase 3 | Endometriosis | Active, not recruiting |
| Jul 2027≤ 340 d | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | ABBVAbbVie | Phase 3 | Myelodysplastic Syndromes | Active, not recruiting |
| Jul 2027≤ 340 d | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan | ABBVAbbVie | Phase 1 | Lung Cancer | Recruiting |
| Jul 2027≤ 340 d | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | ABBVAbbVie | Phase 1 | Chronic Lymphocytic Leukemia | Active, not recruiting |
| Jul 2027≤ 340 d | A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) | ALKSAlkermes, Inc. | Phase 2 | Attention Deficit Disorder With Hyperactivity (ADHD) | Recruiting |
| Jul 2027≤ 340 d | A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp | ALM.MCAlmirall, S.A. | Phase 4 | Keratosis, Actinic | Active, not recruiting |
| 2027-07-31in 340 d | A Study to Evaluate ALN-4915 in Adult Healthy Volunteers | ALNYAlnylam Pharmaceuticals | Phase 1 | Healthy Volunteers | Recruiting |
| 2027-07-31in 340 d | A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | AMGNAmgen | Phase 3 | Age-Related Macular Degeneration | Recruiting |
| 2027-07-31in 340 d | BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA | AZNAstraZeneca | — | COPD | Not yet recruiting |
| 2027-07-31in 340 d | Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel | BMYBristol-Myers Squibb | — | Multiple Myeloma | Active, not recruiting |
| Jul 2027≤ 340 d | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | BPTHBio-Path Holdings, Inc. | Phase 1 | Solid Tumors | Recruiting |
| 2027-07-31in 340 d | Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder | BTAIBioXcel Therapeutics Inc | Phase 1 | Schizophrenia | Recruiting |
| Jul 2027≤ 340 d | Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax | EBSEmergent BioSolutions | — | Anthrax | Not yet recruiting |
| Jul 2027≤ 340 d | A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients | EBSEmergent BioSolutions | — | Inhalational Anthrax | Not yet recruiting |
| Jul 2027≤ 340 d | ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve | EWEdwards Lifesciences | Not applicable | Aortic Stenosis, Severe | Recruiting |
| Jul 2027≤ 340 d | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | JANXJanux Therapeutics | Phase 1 | Prostate Cancer | Recruiting |
| Jul 2027≤ 340 d | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | KRYSKrystal Biotech, Inc. | Phase 1/2 | Melanoma | Recruiting |
| Jul 2027≤ 340 d | A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | LLYEli Lilly and Company | Phase 1 | Alzheimer's Disease | Recruiting |
| Jul 2027≤ 340 d | A Study of LY4088044 in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Recruiting |
| Jul 2027≤ 340 d | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | LLYEli Lilly and Company | Phase 3 | Obesity | Active, not recruiting |
| Jul 2027≤ 340 d | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain | LLYEli Lilly and Company | Phase 2 | Diabetic Peripheral Neuropathic Pain | Recruiting |
| Jul 2027≤ 340 d | A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | LLYEli Lilly and Company | Phase 4 | Type 2 Diabetes | Active, not recruiting |
| Jul 2027≤ 340 d | A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) | LLYEli Lilly and Company | Phase 2 | Irritable Bowel Syndrome, Constipation | Recruiting |
| Jul 2027≤ 340 d | A Study of LY4226695 in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Not yet recruiting |
| Jul 2027≤ 340 d | A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM | LXEOLexeo Therapeutics | — | Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC | Recruiting |
| 2027-07-31in 340 d | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | MAIAMaia Biotechnology | Phase 3 | Carcinoma, Non-Small -Cell Lung | Recruiting |
| Jul 2027≤ 340 d | Personalized Therapy Study - Attain Stability Quad Post-Approval Study | MDTMedtronic | — | Heart Failure | Active, not recruiting |
| Jul 2027≤ 340 d | Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain | MESOMesoblast, Ltd. | Phase 3 | Degenerative Disc Disease | Active, not recruiting |
| Jul 2027≤ 340 d | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | MGNXMacroGenics | Phase 2 | Ovarian Cancer | Recruiting |
| Jul 2027≤ 340 d | Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | NBIXNeurocrine Biosciences | Phase 3 | Major Depressive Disorder | Recruiting |
| Jul 2027≤ 340 d | NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | NBIXNeurocrine Biosciences | Phase 3 | Major Depressive Disorder | Recruiting |
| Jul 2027≤ 340 d | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | NBIXNeurocrine Biosciences | Phase 3 | Major Depressive Disorder | Recruiting |
| Jul 2027≤ 340 d | A Phase 3 Study of NTLA-2001 in ATTRv-PN | NTLAIntellia Therapeutics | Phase 3 | Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease, Neurodegenerative Disease, Hereditary, Neurodegenerative Diseases, Neuromuscular Diseases, Nerve Disorders, Nervous System Disease, Nervous System Diseases, Genetic Disease, Inborn, Amyloidosis, Familial, Amyloidosis, Hereditary, Amyloidosis, Polyneuropathies, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Peripheral Nervous System Disease, Peripheral Nervous System Diseases, Metabolism, Inborn Errors, Metabolic Diseases | Recruiting |
| 2027-07-31in 340 d | General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus | NVONovo Nordisk A/S | — | Type 1 Diabetes | Recruiting |
| 2027-07-31in 340 d | Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania | PFEPfizer | — | Respiratory Syncytial Virus | Active, not recruiting |
| Jul 2027≤ 340 d | WATER IV Prostate Cancer | PRCTPROCEPT BioRobotics | Not applicable | Prostate Cancer | Active, not recruiting |
| 2027-07-31in 340 d | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | TGTXTG Therapeutics, Inc. | Phase 2 | Multiple Sclerosis | Recruiting |
| Jul 2027≤ 340 d | Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study) | TVTXTravere Therapeutics, Inc. | Phase 1/2 | Homocystinuria | Recruiting |
| Jul 2027≤ 340 d | Zimmer Biomet-RibFix Titan | ZBHZimmer Biomet | — | Rib Fracture, Rib Fracture Multiple | Recruiting |
